Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

@article{Martinelli2017CompleteHA,
  title={Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.},
  author={Giovanni Martinelli and Nicolas Boissel and Patrice Chevallier and Oliver Gerhard Ottmann and Nicola G{\"o}kbuget and Max S. Topp and Adele K Fielding and Alessandro Rambaldi and Ellen Ritchie and Cristina Papayannidis and Lulu Ren Sterling and Jonathan Benjamin and Anthony Stein},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2017},
  volume={35 16},
  pages={
          1795-1802
        }
}
Purpose Few therapeutic options are available for patients with Philadelphia chromosome-positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of tyrosine kinase inhibitor (TKI) -based therapy. Here, we evaluated the efficacy and tolerability of blinatumomab in patients with relapsed or refractory Ph+ ALL. Patients and Methods This open-label phase II study enrolled adults with Ph+ ALL who had relapsed after or were refractory to at least one second-generation… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 57 CITATIONS, ESTIMATED 58% COVERAGE

Immunotherapy in adult acute leukemia.

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2017
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 19 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES